No Interaction Between Valproate and Meropenem in a Cirrhotic Patient

Abstract

Get full access to this article

View all access options for this article.

References

, Huang

. Effect of concomitant administration of meropenem and valproic acid in an elderly Chinese patient. Am J Geriatr Pharmacother 2009; 7:26–33. DOI 10.1016/j.amjopharm.2009.02.005

Coves-Orts

, Borrás-Blasco

, Navarro-Ruiz

, Murcia-López

, Palacios-Ortega

. Acute seizures due to a probable interaction between valproic acid and meropenem. Ann Pharmacother 2005; 39:533–7. DOI 10.1345/aph.1E358

Spriet

, Goyens

, Meersseman

, Wilmer

, Willems

, Van Paesschen

. Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother 2007; 41:1130–6. DOI 10.1345/aph.1K079

Haroutiunian

, Ratz

, Rabinovich

, Adam

, Hoffman

. Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study. J Clin Pharmacol 2009; 49:1363–9. DOI 10.1177/0091270009334377

Yamamura

, Imura-Miyoshi

, Naganuma

. Panipenem, a carbapenem antibiotic, increases the level of hepatic UDP-glucuronic acid in rats. Drug Metab Dispos 2000; 28:1484–6.

Nakjima

, Mizobuc

, Nakamura

. Mechanism of the drag interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos 2004; 32:1383–91. DOI 10.1124/dmd.104.000661

Suzuki

, Yamamura

, Ogura

. Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics. Drug Metab Dispos 2010; 38:1538–44. DOI 10.1124/dmd.110.032938

Masuo

, Ito

, Yamamoto

, Hisaka

, Honma

, Suzuki

. Characterization of inhibitory effect of carbapenem antibiotics on the deconjugation of valproic acid glucuronide. Drug Metab Dispos 2010; 38;10: 1828–35. DOI 10.1124/dmd.110.034231

Klotz

, Rapp

, Müller

. Disposition of valproic acid in patients with liver disease. Eur J Clin Pharmacol 1978; 13:55–60. DOI 10.1007/BF00606683

10.

Dasgupta

. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta 2007; 377:1–13. DOI 10.1016/j.cca.2006.08.026

11.

Morgan

, McLean

. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet 1995; 29:370–91. DOI 10.2165/00003088-199529050-00005